Mark A. Watson, M.D., Ph.D.
Pathology and Immunology
Laboratory and Genomic Medicine
Molecular Genetics and Genomics Program
Human and Statistical Genetics Program
In collaboration with other clinical and basic science investigators, we are using biospecimen resources, microarrays, and other ‘whole genome’ technologies to identify genomic signatures that can predict outcome and therapeutic responsiveness in solid organ tumors such as breast and lung cancer. For example, we are developing and validating a gene expression signature to predict malignant potential and clinical consequence of occult tumor cells that are identified in the bone marrow of breast cancer patients. We are also defining differences in the genomes of primary and metastatic lung cancers in order to target therapies specific for patients who have treatment refractory, recurrent disease. Using a technique called Laser Capture Microdissection, we are isolating subpopulations of cells from complex human tissues to address how patterns of gene expression differ between cells within a single tumor and between patients with histologically similar tumors. The long-term goal of these efforts is to use state-of-the-art technology to define and further characterize unique tumor genome signatures that may be applied to the rationale design of new cancer diagnostics and therapeutics.
Ding L, Ellis MJ, Li S, et. al.. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010 15: 999-1005.
Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009 Dec 6 [Epub ahead of print].
Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009 28:3307-3319.
Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR, Watson MA, Gutmann DH, Nagarajan R. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008 27:4745-475.
Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007 13:5001-5009.
Last Updated: 8/4/2011 1:18:55 PM